Datoo MS, Natama MH, Some A, et al. - Stalled progress in controlling Plasmodium falciparum malaria indicates the need for an effective and deployable vaccine. In African children, RTS, S/AS01, the most effective malaria vaccine candidate to date, indicated 56% efficacy over 12 months. Researchers thus assess a new candidate vaccine for safety and efficacy. The low-dose circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children aged 5–17 months in Nanoro, Burkina Faso—a highly seasonal malaria transmission setting in this double-blind, randomized, controlled, phase 2b trial. In this study, 498 children aged 5–17 months were screened between May 7 and June 13, 2019, and 48 were excluded. The results illustrate that in African children, R21/MM seems to be safe and very immunogenic, and demonstrates promising high-level efficacy.